We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Researchers Link PD Risk to Lysosomal Gene Mutations

By LabMedica International staff writers
Posted on 28 Nov 2017
A team of neurodegenerative disease researchers has suggested that multiple genetic defects may act in combination to degrade lysosomal function, which enhances Parkinson’s disease (PD) susceptibility.

Based on previous evidence indicating that mutations in the glucocerebrosidase gene (GBA), which cause Gaucher disease, were also potent risk factors for Parkinson’s disease, investigators at Baylor College of Medicine (Houston, TX, USA) examined whether a genetic burden of variants in other lysosomal storage disorder genes was more broadly associated with Parkinson’s disease susceptibility.

Lysosomal storage disorders are caused by lysosomal dysfunction usually as a consequence of deficiency of a single enzyme required for the metabolism of lipids, glycoproteins, or mucopolysaccharides.

The lysosome is commonly referred to as the cell's recycling center because it processes unwanted material into substances that the cell can utilize. More...
Lysosomes break down this unwanted matter via enzymes. Lysosomal disorders are usually triggered when a particular enzyme exists in too small an amount or is missing altogether. When this happens, excess products destined for breakdown and recycling are stored in the cell. Lysosomal storage diseases affect mostly children and they often die at a young and unpredictable age, many within a few months or years of birth. Many other children die of this disease following years of suffering from various symptoms of their particular disorder.

The investigators used the sequence kernel association test to interrogate variant burden among 54 lysosomal storage disorder genes. The Sequence Kernel Association Test (SKAT) is a tool for region based testing of rare variants from sequencing data. In particular, the SKAT was designed for testing the association of rare variants from sequence data with a dichotomous or quantitative trait. This approach was followed by the leveraging of whole exome sequencing data from 1156 Parkinson’s disease cases and 1679 control subjects.

Results published in the November 13, 2017, online edition of the journal Brain revealed that there was a significant burden of rare, likely damaging lysosomal storage disorder gene variants in association with Parkinson’s disease risk. The majority of Parkinson’s disease cases (56%) had at least one putative damaging variant in a lysosomal storage disorder gene, and 21% carried multiple alleles.

"We studied the largest Parkinson's disease genetic dataset currently available and found that, although each of the damaging mutations within these genes is individually uncommon, they are common as a group within the Parkinson's cohort," said senior author Dr. Joshua Shulman, assistant professor of neurology, neuroscience, and molecular and human genetics at Baylor College of Medicine.

"Although more research remains to be done, these data suggest the interesting possibility that damage to the lysosome might be at the core of Parkinson's disease. It might be possible that Parkinson's disease and lysosomal storage disorders have similar fundamental biological mechanisms."

Related Links:
Baylor College of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.